Inve India ▾

Lincoln Pharmaceuticals share price & results

Lincoln Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q3 FY26
Ownership as of
Sept 2026

Ahmedabad pharma maker of 1,700+ registered generic formulations, exporting to 60+ countries across Africa, Asia and the Americas.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue177 ₹ crore+14.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin15.0 %0.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit36.0 ₹ crore+28.6% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity13.57 %−0.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin12.22 %+0.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)10.00 %+0.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

12 targets tracked, none judged yet · 12 open · verdicts reflect calls analysed to Q3 FY26.

Lincoln Pharmaceuticals Limited management guidance track record on Inve: 12 targets tracked across analysed earnings calls (0 achieved, 0 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue Growth Pace12% to 18%
Call transcript, Q3 FY26 · 23 Feb 2026		Q3 FY26Q3 FY26:Q3 FY26 YoY growth was 13.49%, falling within the target range.
Call transcript, Q3 FY26 · 23 Feb 2026		New

Source: Inve Guidance Tracker for Lincoln Pharmaceuticals Limited · to Q3 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

12 of Lincoln Pharmaceuticals Limited's 12 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 11 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹550.05 +3.93% · +₹20.8

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +4.3% 1Y

₹500₹600₹700Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 23 Feb 2026

1Y: ₹527.35 on 24 Oct 2025 → ₹550.05. High ₹758.15 (27 May 2026), low ₹444.2 (29 Jan 2026).

Previous close
₹529.25
Market cap
₹1.1k Cr
52-week range
₹444.2 – ₹758.15
One year
+4.47%
Price to earnings (TTM to Jun 2026)
10.93×
Return on equity (TTM to Jun 2026)
13.57%

Overview

Symbol
NSE:LINCOLN
Exchange
NSE
Currency
INR

What Lincoln Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Lincoln Pharmaceuticals, incorporated in 1979, develops, manufactures and markets branded-generic pharmaceutical formulations spanning tablets, capsules, dry syrups, ointments, liquid ampoules/vials and dry-powder injectables, across therapeutic areas such as anti-infectives, respiratory, gynecology, cardiovascular, CNS, anti-diabetic and anti-malarial. It sells domestically across most Indian states through a super-stockist distribution network and exports to markets in East and West Africa, Central, North and Latin America, and South East Asia. Manufacturing is carried out at GMP-certified units in Khatraj and Mehsana, Gujarat (including a dedicated Cephalosporin block and a newer bulk-drug manufacturing plant), backed by an in-house R&D team that develops novel drug-delivery formulations and files patents to support new product registrations.

Segments

  • Domestic Sales
  • Exports
Registered products
1,700+ (700+ more in pipeline)
Formulations across therapeutic areas
600+ formulations in 15 therapeutic areas
Team strength
~1,850+ employees including trainees
Export footprint
60+ countries across East & West Africa, Central/North/Latin America and South East Asia
Domestic footprint
26 Indian states
Manufacturing facilities
Two GMP-certified units at Khatraj and Mehsana, Gujarat, plus a separate bulk-drug manufacturing plant
Founded 1979Headquarters Ahmedabad, Gujarat, India Company website

How the price took the results

close before → close after

Q3 FY26
−0.6%
23 Feb

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Lincoln Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Lincoln Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Lincoln Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.